Press Releases
Looking for more press releases? Explore our full press release archive by date to access past announcements, news updates, and media releases published on Iceland Health Focus.
Triple-Track Investment Portfolio: LifeScience Compliance Platform, TV series, and Cat-Human Vocalization
FGC 2.3 Feline Vocalization, Skyward Dragons, and a New Global Regulatory-Affairs SaaS Marketplace NEW YORK CITY, FL, UNITED STATES, June 26, 2025 /EINPresswire.com/ -- Visionary physician-scientist and entrepreneur Dr. Vlad Reznikov, MD, PhD,...
Seaweed Market Worth Observing Growth Rate of 9.5% from 2025 to 2034 | Annie Chun's, Inc., Brandt, Inc., Cargill
WILMINGTON, DE, UNITED STATES, June 17, 2025 /EINPresswire.com/ -- The seaweed market size was valued at $7.5 billion in 2024, and is estimated to reach $18.1 billion by 2034, growing at a CAGR of 9.5% from 2025 to 2034. Seaweed is a diverse...
Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond
ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with...
Open Ocean Robotics Launches First USV for Marine CO₂ Removal Monitoring with Sales to Leading Research Institutions
With initial sales to Dalhousie University and Iceland’s Röst Centre, Open Ocean Robotics introduces first USV built for marine carbon removal monitoring. VICTORIA, BRITISH COLUMBIA, CANADA, May 9, 2025 /EINPresswire.com/ -- Open Ocean Robotics...
Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update
Total Revenues in the first quarter of 2025 reached $132.8 million, compared to $36.9 million in the same period last year, representing a 260% increase Product Revenues in the first in the first quarter of 2025 reached $109.9 million, compared to...
Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
HYDERABAD, India and REYKJAVIK, Iceland, March 18, 2025 (GLOBE NEWSWIRE) -- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”) and Alvotech...
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination of interchangeability for SELARSDI SELARSDI is...
Landmark Study Identifies New Genetic Cause of Neurodevelopmental Disorders, Bringing Long-Awaited Answers to Families
New York, NY, April 10, 2025 (GLOBE NEWSWIRE) -- A seminal study from researchers at the Icahn School of Medicine at Mount Sinai and their collaborators in the United Kingdom, Belgium, Spain, the Netherlands, and Iceland has uncovered a new...
Ligand Reports Fourth Quarter and Full Year 2024 Financial Results
Robust financial performance driven by full year 2024 royalty revenue growth of 28% Reiterating 2025 financial guidance of $180-$200 million in revenues and adjusted earnings per diluted share1 of $6.00-$6.25 Conference call and webcast at 8:30...
Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update
Successful 2024 marked by significant clinical advancements across Oculis’ late-stage and highly differentiated clinical pipeline targeting retina (OCS-01 in diabetic macular edema), neuro-ophthalmic (Privosegtor, OCS-05, in acute optic neuritis)...
Orchard Therapeutics Announces Reimbursement Agreement in Spain
LONDON, MADRID, and BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a Kyowa Kirin company, announced it has recently reached an agreement with the Interministerial Commission for the Pricing of Medicines of the Directorate of...
Orchard Therapeutics Appoints Robin Kenselaar to Chief Commercial Officer and Announces Multiple Business Updates Pertaining to its Approved HSC Gene Therapy for MLD
First U.S. patients being treated with Lenmeldy™ (atidarsagene autotemcel) in a commercial setting; other launch efforts progressing well following Food and Drug Administration approval last year Reimbursement agreement for Libmeldy® reached with...
Joint statement on behalf of 29 partners on aid to Gaza and restrictions facing NGOs
SLOVENIA, August 12 - However, due to restrictive new registration requirements, essential international NGOs may be forced to leave the OPTs imminently which would worsen the humanitarian situation still further. We call on the government of...
Owner: Slovenian Government
Oculis Publishes Invitation to the Annual General Meeting
ZUG, Switzerland, May 09, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), today published the invitation to the 2025 Annual General Meeting, which will be held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11,...
Alvotech Reports Record Results for 2024 and Provides Business Update
Total Revenues in 2024 reached $492 million, representing a 427% increase over prior year Product Revenues in 2024 reached $273 million, representing a 462% increase over prior year Adjusted EBITDA in 2024 was $108.3 million compared to negative...
Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares
ZUG, Switzerland, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with...
Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates
SHANGHAI, March 28, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization...
US Antimicrobial Plastics Market Set to Expand at a 8.20% CAGR, Reaching USD 14.634 Billion by 2032
The US Antimicrobial Plastics market segmentation, based on additive includes Inorganic (Silver, Zinc, Copper) and Organic (ОВРА, Triclosan). NEW YORK, NJ, UNITED STATES, April 29, 2025 /EINPresswire.com/ -- The US Antimicrobial Plastics Market...